Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
1 competitor in Bronchiectasis
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Arikayce
Arikayce is indicated for: treatment of Mycobacterium avium Complex (MAC) lung disease in adult patients who have persistent positive sputum cultures despite the use of medically appropriate first-line therapy Consideration should be given to official guidance on the appropriate use of antibacterial agents. Arikayce should be added to existing therapy and should not be used as monotherapy.
View on EMAPseudomonas Aeruginosa Infection
Cystic Fibrosis
Non-Cystic Fibrosis Bronchiectasis
NTM Lung Infection Due to MAC
Pulmonary Hypertension